# Point of Care Diagnostic test for Molecular Subtyping of Breast Cancer (PoCBreCa Study)

> **NIH NIH R21** · UNIVERSITY OF MARYLAND BALTIMORE · 2022 · $176,683

## Abstract

Point of Care Diagnostic test for Molecular Subtyping of Breast Cancer (PoCBreCa) Study
Project Summary
 The incidence of breast cancer in low and middle-income countries (LMIC) is rising rapidly. Despite this,
very little is known about the epidemiology of molecular subtypes of breast cancer in these countries because of
lack of facilities, resources and personnel for immunohistochemistry (IHC), the current gold standard for
molecular subtyping of breast cancer. Innovative strategies that combine nanotechnology, photonics,
miniaturization and cell phone networks to develop new technologies and kits can overcome these limitations
and increase availability of molecular subtyping of breast cancer in LMIC.
 Increased availability of molecular subtyping will enable epidemiological research into the determinants
and secular trend in the incidence of molecular subtypes of breast cancer in LMIC where previous studies have
yielded conflicting results. It will also empower clinicians in their choice of breast cancer treatment, prediction of
response and prognosis. The kits that we propose to develop in this project will generate quantitative results
which will open new research and treatment opportunities for precision medicine based on quantitative levels of
hormone receptors, its determinants and associations with germline and somatic, genetic and epigenetic
variations.
 In this project, researchers at University of Maryland School of Medicine, Baltimore and Cornell University
in the United States, and Center for Bioethics and Research, and the University of Ibadan in Nigeria work
together to develop and pilot-test a point of care diagnostic kit for molecular subtyping of breast tumors and
compare it to IHC in order to overcome current challenges and open new opportunities for breast cancer
research.

## Key facts

- **NIH application ID:** 10348749
- **Project number:** 5R21CA255835-02
- **Recipient organization:** UNIVERSITY OF MARYLAND BALTIMORE
- **Principal Investigator:** Clement Adebayo Adebamowo
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $176,683
- **Award type:** 5
- **Project period:** 2021-02-10 → 2025-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10348749

## Citation

> US National Institutes of Health, RePORTER application 10348749, Point of Care Diagnostic test for Molecular Subtyping of Breast Cancer (PoCBreCa Study) (5R21CA255835-02). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10348749. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*